Literature DB >> 18997456

Susceptibility to hyperglycemia in patients with chronic kidney disease.

Walid Shehab-Eldin1, Ali Zaki, Sanaa Gazareen, Ahmed Shoker.   

Abstract

BACKGROUND: Patients with chronic kidney disease (CKD) are susceptible to hyperglycemia. AIM: To study the prevalence of pre-diabetes in CKD patients and determine the contribution of insulin resistance (IR) versus beta-cell dysfunction in patients with CKD.
METHODS: 45 consecutive nondiabetic CKD patients and 40 healthy subjects were included. Patients were divided into a normoglycemic (NG) and a pre-diabetic (PDM) group. IR was assessed by homeostasis model assessment of insulin resistance (HOMA-IR) and beta-cell function was assessed by proinsulin/insulin ratio and beta-cell%.
RESULTS: The prevalence of PDM was 40%. The prevalence of high HOMA-IR was 22.2 and 77.8% in the NG and PDM groups. Compared to NG patients, the PDM group showed higher fasting plasma glucose, HOMA-IR, insulin, and proinsulin, while the prevalence of beta-cell dysfunction of 22.2% was lower than the 37% present in the NG group.
CONCLUSION: Increased IR, rather than beta-cell dysfunction, is the primary mechanism of PDM in CKD patients. Copyright (c) 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18997456     DOI: 10.1159/000171379

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  2 in total

1.  Deletion of the insulin receptor in the proximal tubule promotes hyperglycemia.

Authors:  Swasti Tiwari; Ravi Shankar Singh; Lijun Li; Susanna Tsukerman; Madan Godbole; Gaurav Pandey; Carolyn M Ecelbarger
Journal:  J Am Soc Nephrol       Date:  2013-05-30       Impact factor: 10.121

2.  Homeostatic model assessment indices in evaluation of insulin resistance and secretion in hemodialysis patients.

Authors:  Stanisław Niemczyk; Katarzyna Szamotulska; Kinga Giers; Mariusz Jasik; Zbigniew Bartoszewicz; Katarzyna Romejko-Ciepielewska; Ewa Paklerska; Małgorzata Gomółka; Joanna Matuszkiewicz-Rowińska
Journal:  Med Sci Monit       Date:  2013-07-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.